For the quarter ending 2026-03-31, CUE made $5,686K in revenue. -$5,178K in net income. Net profit margin of -91.07%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | 5,686 | 21,942 | 2,149 | 2,954 |
| General and administrative | 4,152 | 3,453 | 4,939 | 3,679 |
| Research and development | 6,897 | 16,532 | 4,754 | 7,910 |
| Gain (loss) on fixed asset disposal | - | 20 | -51 | - |
| (gain) on lease termination | 10 | - | - | - |
| Total operating expenses | 11,039 | 19,965 | 9,744 | 11,589 |
| Gain from operations | -5,353 | 1,977 | -7,595 | -8,635 |
| Interest income | 179 | 217 | 222 | 198 |
| Interest expense | -4 | -109 | -75 | -45 |
| Total other income, net | 175 | 108 | 147 | 153 |
| Loss before provision for income taxes | - | -1,710* | - | - |
| Provision for income taxes | - | 125* | - | - |
| Net gain | -5,178 | 1,585 | -7,448 | -8,482 |
| Unrealized gain from available-for-sale securities | - | - | 1 | - |
| Comprehensive loss | - | - | -7,447 | -8,482 |
| Basic EPS | -1.08 | 0.015 | -0.07 | -0.09 |
| Diluted EPS | -1.08 | 0.015 | -0.07 | -0.09 |
| Basic Average Shares | 4,807,494 | 108,343,622 | 100,869,349 | 95,459,401 |
| Diluted Average Shares | 4,807,494 | 108,343,622 | 100,869,349 | 95,459,401 |
Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc. (CUE)